Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation

Ryusuke Yamamoto; Nobuhiro Hiramoto; Ayumi Fujimoto; Hirohito Yamazaki; Takehiko Mori; Naoyuki Uchida; Noriko Doki; Jun Kato; Masashi Nishikubo; Shinichi Kako; Tetsuya Nishida; Shuichi Ota; Makoto Onizuka; Tetsuya Eto; Koichi Onodera; Kazuhiro Ikegame; Ken-Ichi Matsuoka; Yoshinobu Kanda; Takahiro Fukuda; Yoshiko Atsuta; Yasushi Onishi

doi:10.1038/s41409-024-02234-1

Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation

Bone Marrow Transplant. 2024 May;59(5):688-691. doi: 10.1038/s41409-024-02234-1. Epub 2024 Feb 10.

Authors

Ryusuke Yamamoto¹, Nobuhiro Hiramoto², Ayumi Fujimoto³, Hirohito Yamazaki⁴, Takehiko Mori⁵, Naoyuki Uchida⁶, Noriko Doki⁷, Jun Kato⁸, Masashi Nishikubo¹, Shinichi Kako⁹, Tetsuya Nishida¹⁰, Shuichi Ota¹¹, Makoto Onizuka¹², Tetsuya Eto¹³, Koichi Onodera¹⁴, Kazuhiro Ikegame¹⁵, Ken-Ichi Matsuoka¹⁶, Yoshinobu Kanda¹⁷, Takahiro Fukuda¹⁸, Yoshiko Atsuta^{19

20}, Yasushi Onishi¹⁴

Affiliations

¹ Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
² Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan. kvlqt1789@gmail.com.
³ Department of Hematology, Shimane University Hospital, Izumo, Japan.
⁴ Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.
⁵ Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
⁶ Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan.
⁷ Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
⁸ Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
⁹ Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
¹⁰ Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
¹¹ Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
¹² Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
¹³ Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
¹⁴ Department of Hematology, Tohoku University Hospital, Sendai, Japan.
¹⁵ Department of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
¹⁶ Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
¹⁷ Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
¹⁸ Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
¹⁹ Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
²⁰ Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.

PMID: 38341498
DOI: 10.1038/s41409-024-02234-1

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Allografts
Anemia, Aplastic* / therapy
Antilymphocyte Serum* / therapeutic use
Child
Female
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Lymphoproliferative Disorders* / etiology
Male
Middle Aged
Retrospective Studies
Risk Assessment
Transplantation, Homologous
Young Adult

Substances

Antilymphocyte Serum